Silence Therapeutics plc (LON:SLN) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $76.58 and traded as low as $196.00. Silence Therapeutics shares last traded at $206.00, with a volume of 26,923 shares traded.
Separately, Peel Hunt reissued a “buy” rating on shares of Silence Therapeutics in a research note on Thursday, August 1st.
The firm has a market cap of $158.80 million and a P/E ratio of -7.81. The company’s 50 day simple moving average is GBX 147.06 and its 200-day simple moving average is GBX 78.46.
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.